New drug TTX-MC138 tested in patients with advanced solid tumors
NCT ID NCT06260774
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This early-phase study tests a new drug called TTX-MC138 in 16 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink or stabilize tumors. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77230, United States
-
Mary Crowley Cancer Center
Dallas, Texas, 75230, United States
-
Next Oncology
Fairfax, Virginia, 22031, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
Conditions
Explore the condition pages connected to this study.